商品编号


YIF-LF-P0311



品牌


Adipogen



公司


Adipogen



公司分类


Proteins



Size

0.1 mg

商品信息


More Information



Product Details



Synonyms

UCHL1; PGP9.5; UCH-L1; PGP 9.5; EC=3.4.19.12; Ubiquitin Thioesterase L1; Neuron Cytoplasmic Protein 9.5; Ubiquitin Carboxyl-terminal Hydrolase Isozyme L1



Product Type

Protein



Properties



Source/Host

E. coli



Crossreactivity

Human



Purity

≥90% (SDS-PAGE)



Formulation

Lyophilized from 50mM Tris, pH8.0 / 10mM GSH.



Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.



Declaration

Manufactured by AbFrontier



Shipping and Handling



Shipping

BLUE ICE



Short Term Storage

+4°C



Long Term Storage

-20°C



Handling Advice

Avoid freeze/thaw cycles.



Use/St
ABI
lity

After reconstitution, store at -80°C.



Documents



MSD
S

No



Product Specification Sheet



Datasheet


Download PDF





Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) is a deubiqutinating enzyme. Ubiquitin UCHL1, also known as PGP9.5, is a protein of 223 amino acids and one of the most abundant proteins in the brain (1~2% of the total soluble protein). Although it was originally characterized as a deubiquitinating enzyme recent studies indicate that it also functions as a ubiquitin (Ub) ligase and a mono-Ub st
ABI
lizer. A large amount of mono-Ub is tightly associated with UCHL1, inhibiting the degradation of mono-Ub in the brain. The precise regulation of UCHL1 is essential for neurons to survive and to maintain their proper function. UCHL1 is involved in the pathogenesis of Parkinson’s disease (PD) and Alzheimer's disease (AD). Down-regulation and extensive oxidative modification of UCHL1 have been observed in the brains of AD patients as well as PD patients. A post-translational modification of UCHL1 that controls the function of UCHL1 is mono-ubiquitination. It occurs revers
IBL
y to a lysine residue near the active site of UCHL1.


Product References
1) Setsuie Rand Wada K, (2007) Neu
Roche
m Int. 51(2-4):105-111. (General)
2) Gong B and Leznik E, (2007) Drug News Perspect. 20(6):365-370. (General)
3) Betarbet R et al. (2005) Exp Neurol. 191 Suppl 1:S17-27. (General)